Alerts

Magno-Humphries Laboratories Inc is voluntarily recalling Basic Drugs Brand Senna Laxative tablets due to mislabeling concerns.

The FDA is now requiring new information in the labeling of these products describing the risks of use in children or breastfeeding women.

The manufacturer, Tesaro, recommends that healthcare providers watch for hypersensitivity or anaphylaxis during and following rolapitant administration.

Gadolinium-based contrast agents (GBCAs) can remain in patients’ bodies for months to years after administration.

FDA issued a MedWatch alert concerning the use of Limbrel and risk of drug-induced liver injury and hypersensitivity pneumonitis.

Fresenius Kabi USA is recalling midazolam injection 2 mg/2 mL prefilled syringes due to mislabeling concerns.

The FDA issued a communication detailing an approach to possibly continue benzodiazepines or CNS depressants with opioid addiction medications, buprenorphine or methadone.

The FDA published an alert describing hemorrhagic occlusive retinal vasculitis (HORV) associated with compounded triamcinolone, moxifloxacin, and vancomycin (TMV) intraocular injection from Imprimis Pharmaceuticals, Inc.

Sodium polystyrene sulfonate, known by the brand name Kayexalate, binds to commonly used oral medications, decreasing their absorption and potentially their effectiveness.

Pembrolizumab (Keytruda) in combination with dexamethasone and either lenalidomide or pomalidomide increased the risk of death in patients with multiple myeloma based on interim analyses from 2 phase 3 clinical...

The PharmaTech recall of oral liquid docusate products has been expanded. FDA now recommends not using any liquid products manufactured by PharmaTech.

The FDA is warning of high levels of lead in the supplement, Balguti Kesaria Ayurvedic.

Amneal is voluntarily recalling certain lots of lorazepam 2 mg/mL oral concentrate (NDC 65162-0687-84), which contain misprinted dosing droppers.

International Laboratories, LLC is voluntarily recalling pravastatin 40 mg tablets due to mislabeling concerns.

Apace Packaging LLC is voluntarily recalling one lot each of cyclobenzaprine and amantadine 50-count unit dose boxes due to mislabeling concerns.

The device cartridge may break or crack if exposed to chemicals or cleaning agents.

AstraZeneca is voluntarily recalling ticagrelor (Brilinta) 90 mg physician sample bottles because they may also contain lesinurad (Zurampic) 200 mg tablets, another AstraZeneca product.

Lupin Pharmaceuticals Inc. recalled lot L600518, expiry 05/18 of Mibelas 24 Fe (norethindrone acetate and ethinyl estradiol 1 mg/0.02 mg and ferrous fumarate 75 mg) chewable tablets.

Genetic Edge Compounds is voluntarily recalling GEC Laxoplex due to FDA concerns regarding the presence of anabolic steroids and other steroid-like substances.

Hospira Inc., is voluntarily recalling one lot (NDC 0408-1775-10, Lot # 58382EV) of 25% Dextrose Injection, USP (Infant) prefilled syringes.

FDA approved a new warning in the product labeling reflecting this risk.

FDA is warning consumers and health care professionals that several companies have sold products illegally claiming to prevent, diagnose, treat, or cure cancer.

The FDA has discontinued the Risk Evaluation Mitigation Strategy (REMS) program for the erythropoiesis-stimulating agents (ESAs).

FDA issued a warning about the risk of adverse effects from all homeopathic teething tablets and gels. The company has agreed to conduct a recall of their belladonna homeopathic teething...